Clinical trial
A Phase I Trial of Sorafenib and LBH589 in the Treatment of Advanced HCC
NCT00823290 is registered in ClinicalTrials.gov with University of Erlangen-Nürnberg Medical School as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Trial of Sorafenib and LBH589 in the Treatment of Advanced HCC
- Lead sponsor
- University of Erlangen-Nürnberg Medical School
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- January 31, 2009
- Completion date
- December 31, 2010
- Enrollment
- 2 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hepatocellular carcinoma